Novelty Nobility Expands AGC Biologics Partnership for Bispecific Antibody Manufacturing

Key Takeaways

• Novelty Nobility expanded its manufacturing agreement with AGC Biologics to advance bispecific antibody development
• The partnership will utilize AGC Biologics’ GMP manufacturing facility in Chiba, Japan for process development
• This collaboration represents a strategic move to accelerate the clinical development of innovative bispecific therapeutics

---

Novelty Nobility Strengthens Manufacturing Partnership

South Korean clinical-stage biotechnology company Novelty Nobility announced on May 4, 2026, an expanded manufacturing agreement with AGC Biologics to advance development of its bispecific antibody drug candidate. The enhanced partnership will leverage AGC Biologics’ specialized contract development and manufacturing organization (CDMO) capabilities at their facility in Chiba, Japan.

Strategic Manufacturing Alliance

The expanded agreement encompasses both process development and Good Manufacturing Practice (GMP) manufacturing services for Novelty Nobility’s bispecific antibody candidate. This collaboration builds upon an existing relationship between the two companies, demonstrating confidence in AGC Biologics’ manufacturing expertise and infrastructure.

Bispecific antibodies represent a cutting-edge therapeutic approach that can simultaneously target two different antigens or bind to two different sites on the same antigen. This dual-targeting capability offers potential advantages in treating complex diseases, particularly in oncology and autoimmune conditions.

Market Implications and Industry Context

The partnership reflects the growing demand for specialized manufacturing capabilities in the bispecific antibody market, which has seen increased investment and development activity. AGC Biologics’ Chiba facility provides the technical expertise and regulatory compliance necessary for advancing complex biologics through clinical development.

For Novelty Nobility, this manufacturing partnership represents a critical step in advancing their bispecific candidate toward clinical trials. The company’s decision to expand their existing agreement with AGC Biologics suggests positive progress in their development program and confidence in the manufacturing partner’s capabilities.

Future Development Timeline

The expanded manufacturing agreement positions Novelty Nobility to advance their bispecific antibody candidate through the necessary process development and manufacturing stages required for clinical testing. AGC Biologics’ established GMP manufacturing capabilities and regulatory expertise will be essential for meeting the stringent requirements of clinical-grade drug production.

---

Frequently Asked Questions

What are bispecific antibodies and why are they important?

Bispecific antibodies are engineered therapeutic proteins that can simultaneously target two different antigens or binding sites, offering potentially superior efficacy compared to traditional single-target antibodies, particularly in cancer and autoimmune diseases.

When will Novelty Nobility’s bispecific antibody be available to patients?

The drug candidate is still in development stages with process development and GMP manufacturing currently underway. Clinical trials and regulatory approval would be required before patient availability, which typically takes several years.

Why did Novelty Nobility choose AGC Biologics for manufacturing?

AGC Biologics offers specialized CDMO expertise in complex biologics manufacturing, GMP-compliant facilities in Japan, and an existing successful partnership with Novelty Nobility, making them a strategic choice for advancing bispecific antibody development.